Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2023 Filed Oct 6, 2023 11:10 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 2,000 | $6.47 | $12,940.00 |
DisclosureSEC source: 0001628280-23-034004 · wf-form4_169659064199177.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,451 Read SEC document |
| October 04, 2023 Filed Oct 4, 2023 21:30 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 5,000 | $6.40 | $32,000.00 |
DisclosureSEC source: 0001628280-23-033842 · wf-form4_169645502108268.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,451 Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 21:31 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 2,500 | $6.30 | $15,750.00 |
DisclosureSEC source: 0001628280-23-033843 · wf-form4_169645505352839.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,451 Read SEC document |
| September 29, 2023 Filed Oct 16, 2023 13:53 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 4,000 | $6.16 | $24,640.00 |
DisclosureSEC source: 0001628280-23-034409 · wk-form4_1697464428.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,581 Read SEC document |
| September 28, 2023 Filed Oct 16, 2023 13:52 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 5,000 | $6.22 | $31,100.00 |
DisclosureSEC source: 0001628280-23-034407 · wk-form4_1697464350.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,581 Read SEC document |
| September 27, 2023 Filed Oct 16, 2023 13:51 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 1,500 | $5.95 | $8,925.00 |
DisclosureSEC source: 0001628280-23-034405 · wk-form4_1697464252.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,581 Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 13:56 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 5,000 | $5.65 | $28,250.00 |
DisclosureSEC source: 0001628280-23-033077 · wf-form4_169582300558310.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,951 Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 18:59 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 3,812 | $5.50 | $20,966.00 |
DisclosureSEC source: 0001628280-23-032917 · wf-form4_169566833604307.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,951 Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 18:59 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 5,000 | $5.51 | $27,550.00 |
DisclosureSEC source: 0001628280-23-032918 · wf-form4_169566835107905.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,139 Read SEC document |
| September 20, 2023 Filed Sep 25, 2023 18:59 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 4,018 | $5.51 | $22,139.18 |
DisclosureSEC source: 0001628280-23-032919 · wf-form4_169566837025005.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,139 Read SEC document |
| September 19, 2023 Filed Sep 25, 2023 19:00 UTC |
Mendelson Daniel NewmanDirector
|
PurchaseCommon Stock | 5,000 | $5.28 | $26,400.00 |
DisclosureSEC source: 0001628280-23-032920 · wf-form4_169566838737069.xml · nonDerivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,121 Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 16:30 UTC |
Morris RonnieDirector · CEO
|
PurchaseCommon Stock | 12,382 | $4.04 | $49,968.80 |
DisclosureSEC source: 0001628280-23-008699 · wf-form4_167941620961163.xml · nonDerivative · entry 1 Morris Ronnie · CIK 0001504443 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 858,878 Read SEC document |
| November 01, 2022 Filed Aug 17, 2023 16:10 UTC |
ACKERMAN JOELDirector
|
GrantOption to purchase Common Stock · Derivative | 26,500 | $7.00 Strike: $7.00 | $185,500.00 |
DisclosureSEC source: 0001628280-23-029779 · wf-form4_169228859069507.xml · derivative · entry 1 ACKERMAN JOEL · CIK 0001220630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2032-11-01 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| November 01, 2022 Filed Aug 17, 2023 16:09 UTC |
Breitfeld Philip P.Director
|
GrantOption to purchase Common Stock · Derivative | 11,480 | $7.00 Strike: $7.00 | $80,360.00 |
DisclosureSEC source: 0001628280-23-029778 · wf-form4_169228853672738.xml · derivative · entry 1 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,480 Underlying: Common Stock · 11,480 shares Expires 2032-11-01 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1,2023, respectively. Read SEC document |
| November 01, 2022 Filed Aug 17, 2023 16:07 UTC |
Mendelson Daniel NewmanDirector
|
GrantOption to purchase Common Stock · Derivative | 19,430 | $7.00 Strike: $7.00 | $136,010.00 |
DisclosureSEC source: 0001628280-23-029777 · wf-form4_169228846413492.xml · derivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,430 Underlying: Common Stock · 19,430 shares Expires 2032-11-01 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| November 01, 2022 Filed Aug 17, 2023 16:05 UTC |
SIDRANSKY DAVIDDirector
|
GrantOption to purchase Common Stock · Derivative | 11,480 | $7.00 Strike: $7.00 | $80,360.00 |
DisclosureSEC source: 0001628280-23-029776 · wf-form4_169228834017538.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,480 Underlying: Common Stock · 11,480 shares Expires 2032-11-01 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| November 01, 2022 Filed Aug 17, 2023 16:04 UTC |
TOBIN SCOTT RDirector · 10% owner
|
GrantOption to purchase Common Stock · Derivative | 21,200 | $7.00 Strike: $7.00 | $148,400.00 |
DisclosureSEC source: 0001628280-23-029775 · wf-form4_169228823891977.xml · derivative · entry 1 TOBIN SCOTT R · CIK 0001199926 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,200 Underlying: Common Stock · 21,200 shares Expires 2032-11-01 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| November 01, 2022 Filed Jan 30, 2026 17:15 UTC |
Brainin Robert LawrenceDirector
|
GrantOption to purchase Common Stock · Derivative | 14,130 | $7.00 Strike: $7.00 | $98,910.00 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 2 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,063 Underlying: Common Stock · 14,130 shares Expires 2032-11-01 F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 17:26 UTC |
ACKERMAN JOELDirector
|
Exercise / conversionOption to purchase Common Stock · Derivative | 16,667 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001628280-22-026743 · wf-form4_166628679804291.xml · derivative · entry 2 ACKERMAN JOEL · CIK 0001220630 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 8, 2017, February 8, 2018, May 8, 2018 and August 8, 2018, respectively. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 17:26 UTC |
ACKERMAN JOELDirector
|
Exercise / conversionCommon Stock | 16,667 | $3.21 | $53,501.07 |
DisclosureSEC source: 0001628280-22-026743 · wf-form4_166628679804291.xml · nonDerivative · entry 1 ACKERMAN JOEL · CIK 0001220630 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 13:00 UTC |
TOBIN SCOTT RDirector
|
Exercise / conversionStock Options · Derivative | 10,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001415889-22-010488 · form4-10132022_061018.xml · derivative · entry 2 TOBIN SCOTT R · CIK 0001199926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 13:00 UTC |
TOBIN SCOTT RDirector
|
Exercise / conversionCommon Stock | 10,000 | $3.21 | $32,100.00 |
DisclosureSEC source: 0001415889-22-010488 · form4-10132022_061018.xml · nonDerivative · entry 1 TOBIN SCOTT R · CIK 0001199926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:25 UTC |
Breitfeld Philip P.Director
|
Exercise / conversionOption to purchase Common Stock · Derivative | 8,333 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001628280-22-026398 · wf-form4_166577191015059.xml · derivative · entry 3 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 8, 2017, February 8, 2018, May 8, 2018 and August 8, 2018 Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:25 UTC |
Breitfeld Philip P.Director
|
Tax withholdingCommon Stock | 3,562 | $7.51 | $26,750.62 |
DisclosureSEC source: 0001628280-22-026398 · wf-form4_166577191015059.xml · nonDerivative · entry 2 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 F1 · kind: Represents a "net exercise" of outstanding stock opitons. These shares were witheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, common stock on October 12, 2022. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:25 UTC |
Breitfeld Philip P.Director
|
Exercise / conversionCommon Stock | 8,333 | $3.21 | $26,748.93 |
DisclosureSEC source: 0001628280-22-026398 · wf-form4_166577191015059.xml · nonDerivative · entry 1 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:27 UTC |
SIDRANSKY DAVIDDirector
|
Exercise / conversionOption to purchase Common Stock · Derivative | 8,333 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001628280-22-026400 · wf-form4_166577200797332.xml · derivative · entry 3 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 8, 2017, February 8, 2018, May 8, 2018 and August 8, 2018 Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:27 UTC |
SIDRANSKY DAVIDDirector
|
Tax withholdingCommon Stock | 3,562 | $7.51 | $26,750.62 |
DisclosureSEC source: 0001628280-22-026400 · wf-form4_166577200797332.xml · nonDerivative · entry 2 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,043 F1 · kind: Represents a "net exercise" of outstanding stock opitons. These shares were witheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, common stock on October 12, 2022. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 18:27 UTC |
SIDRANSKY DAVIDDirector
|
Exercise / conversionCommon Stock | 8,333 | $3.21 | $26,748.93 |
DisclosureSEC source: 0001628280-22-026400 · wf-form4_166577200797332.xml · nonDerivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:31 UTC |
Mendelson Daniel NewmanDirector
|
GrantOption to purchase Common Stock · Derivative | 13,614 | $10.10 Strike: $10.10 | $137,501.40 |
DisclosureSEC source: 0001628280-21-022606 · wf-form4_163649710448444.xml · derivative · entry 1 Mendelson Daniel Newman · CIK 0001327897 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,614 Underlying: Common Stock · 13,614 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:32 UTC |
SIDRANSKY DAVIDDirector
|
GrantOption to purchase Common Stock · Derivative | 8,045 | $10.10 Strike: $10.10 | $81,254.50 |
DisclosureSEC source: 0001628280-21-022608 · wf-form4_163649714939624.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045 Underlying: Common Stock · 8,045 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:31 UTC |
Breitfeld Philip P.Director
|
GrantOption to purchase Common Stock · Derivative | 8,045 | $10.10 Strike: $10.10 | $81,254.50 |
DisclosureSEC source: 0001628280-21-022605 · wf-form4_163649706826161.xml · derivative · entry 1 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045 Underlying: Common Stock · 8,045 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5,2022, respectively. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:29 UTC |
TOBIN SCOTT RDirector · 10% owner
|
GrantOption to purchase Common Stock · Derivative | 14,851 | $10.10 Strike: $10.10 | $149,995.10 |
DisclosureSEC source: 0001628280-21-022603 · wf-form4_163649697182669.xml · derivative · entry 1 TOBIN SCOTT R · CIK 0001199926 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,851 Underlying: Common Stock · 14,851 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:30 UTC |
ACKERMAN JOELDirector
|
GrantOption to purchase Common Stock · Derivative | 18,564 | $10.10 Strike: $10.10 | $187,496.40 |
DisclosureSEC source: 0001628280-21-022604 · wf-form4_163649701340351.xml · derivative · entry 1 ACKERMAN JOEL · CIK 0001220630 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,564 Underlying: Common Stock · 18,564 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
| November 05, 2021 Filed Jan 30, 2026 17:15 UTC |
Brainin Robert LawrenceDirector
|
GrantOption to purchase Common Stock · Derivative | 9,901 | $10.10 Strike: $10.10 | $100,000.10 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 1 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,933 Underlying: Common Stock · 9,901 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 19:39 UTC |
SIDRANSKY DAVIDDirector
|
GrantOption to purchase Common Stock · Derivative | 16,667 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-21-020221 · wf-form4_163467237424646.xml · derivative · entry 3 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2021-11-01 F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017, respectively. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 19:39 UTC |
SIDRANSKY DAVIDDirector
|
Tax withholdingCommon Stock | 2,629 | $10.08 | $26,500.32 |
DisclosureSEC source: 0001628280-21-020221 · wf-form4_163467237424646.xml · nonDerivative · entry 2 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 762,272 F1 · kind: Represents a "net exercise" of outstanding stock options. The shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on October 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 19:39 UTC |
SIDRANSKY DAVIDDirector
|
Exercise / conversionCommon Stock | 16,667 | $1.59 | $26,500.53 |
DisclosureSEC source: 0001628280-21-020221 · wf-form4_163467237424646.xml · nonDerivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 14:26 UTC |
TOBIN SCOTT RDirector
|
Exercise / conversionStock Options · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-21-009382 · edgar.xml · derivative · entry 2 TOBIN SCOTT R · CIK 0001199926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 14:26 UTC |
TOBIN SCOTT RDirector
|
Exercise / conversionCommon Stock | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001179110-21-009382 · edgar.xml · nonDerivative · entry 1 TOBIN SCOTT R · CIK 0001199926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 19:27 UTC |
Breitfeld Philip P.Director
|
Exercise / conversionOption to purchase Common Stock · Derivative | 4,167 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001628280-21-005610 · wf-form4_161670040991722.xml · derivative · entry 3 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires 2021-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and are exercisable over a four month period, with vesting to occur on May 1, 2016 and August 1, 2016, respectively. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 19:27 UTC |
Breitfeld Philip P.Director
|
Tax withholdingCommon Stock | 1,340 | $11.35 | $15,209.00 |
DisclosureSEC source: 0001628280-21-005610 · wf-form4_161670040991722.xml · nonDerivative · entry 2 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,827 F1 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on March 23, 2021. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 19:27 UTC |
Breitfeld Philip P.Director
|
Exercise / conversionCommon Stock | 4,167 | $3.65 | $15,209.55 |
DisclosureSEC source: 0001628280-21-005610 · wf-form4_161670040991722.xml · nonDerivative · entry 1 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 7 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 4, 2019, February 4, 2020, May 4, 2020 and August 4, 2020, respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 6 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2017, February 1, 2018, May 1, 2018 and August 1, 2018, respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 5 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017 respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Tax withholdingCommon Stock | 8,873 | $11.53 | $102,305.69 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 4 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,274 F1 · kind: Represents a "net exercise" of outstanding stock options. The shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on January 19,2021. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionCommon Stock | 10,000 | $5.43 | $54,300.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 3 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionCommon Stock | 10,000 | $3.21 | $32,100.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 2 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC |
Poliakoff Abba DavidDirector
|
Exercise / conversionCommon Stock | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 14:29 UTC |
Breitfeld Philip P.Director
|
SaleCommon Stock | 31,443 | $11.35 | $356,975.52 |
DisclosureSEC source: 0001628280-20-017581 · wf-form4_160821535638533.xml · nonDerivative · entry 1 Breitfeld Philip P. · CIK 0001690133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.